Related Experiment Videos
[Intraamniotic surfactant supply as RDS prevention].
Jacek Lisawa1, Dariusz Pietrasik, Jerzy Zwoliński
1Klinika Połoznictwa i Ginekologii IMD, Instytut Matki i Dziecka w Warszawie.
Medycyna Wieku Rozwojowego
|November 13, 2004
Summary
Antenatal steroids and postnatal surfactant are established treatments for respiratory distress syndrome (RDS). Intra-amniotic surfactant, administered before birth, shows promise for RDS prevention with no observed complications in this preliminary study.
Area of Science:
- Neonatal Medicine
- Pulmonology
- Obstetrics
Context:
- Respiratory Distress Syndrome (RDS) is a significant cause of neonatal morbidity and mortality.
- Antenatal corticosteroids and postnatal surfactant therapy are current standards of care but have limitations.
- Novel strategies for RDS prevention are actively being researched.
Purpose:
- To evaluate the safety and efficacy of intra-amniotic surfactant administration for preventing RDS.
- To assess the feasibility of delivering surfactant directly into the amniotic cavity prior to delivery.
- To investigate the role of provoking fetal breathing movements before surfactant instillation.
Summary:
- Natural surfactant was administered intra-amniotically to 15 pregnant women between 24-32 weeks gestation, prior to scheduled delivery.
- Ultrasound guidance was used for surfactant instillation near the fetal airway; Aminophylline was given to stimulate fetal breathing.
- No procedural complications were noted, and newborns showed reduced severe asphyxia and no need for postpartum surfactant therapy.
Impact:
- Intra-amniotic surfactant instillation appears to be a safe and potentially effective method for RDS prevention.
- Preliminary results suggest a favorable outcome for newborns, with a high survival rate and reduced need for mechanical ventilation.
- Further research with larger cohorts is warranted to confirm these encouraging findings and establish clinical utility.